111 related articles for article (PubMed ID: 32657670)
1. Hepatoprotective Effect of
Chiou YL; Chyau CC; Li TJ; Kuo CF; Kang YY; Chen CC; Ko WS
J Am Coll Nutr; 2021; 40(4):349-357. PubMed ID: 32657670
[TBL] [Abstract][Full Text] [Related]
2.
Yen IC; Lin JC; Chen Y; Tu QW; Lee SY
Am J Chin Med; 2020; 48(8):1859-1874. PubMed ID: 33308101
[TBL] [Abstract][Full Text] [Related]
3. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
[TBL] [Abstract][Full Text] [Related]
4. Patient-Derived Tumor Chemosensitization of GKB202, an
Li TJ; Lin TW; Wu SP; Chu HT; Kuo YH; Chiou JF; Lu LS; Chen CC
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641562
[TBL] [Abstract][Full Text] [Related]
5. Hepatoprotective effect of
Ho CY; Kuan CM; Hsu PK
J Diet Suppl; 2023; 20(6):939-949. PubMed ID: 36476310
[No Abstract] [Full Text] [Related]
6. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.
Dasarathy S; Dasarathy J; Khiyami A; Yerian L; Hawkins C; Sargent R; McCullough AJ
J Clin Gastroenterol; 2015 Feb; 49(2):137-44. PubMed ID: 24583757
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
[TBL] [Abstract][Full Text] [Related]
8. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C; Nik Mustapha NR; Mahadeva S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
[TBL] [Abstract][Full Text] [Related]
10. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
11. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
13. Antroquinonol from ethanolic extract of mycelium of Antrodia cinnamomea protects hepatic cells from ethanol-induced oxidative stress through Nrf-2 activation.
Kumar KJ; Chu FH; Hsieh HW; Liao JW; Li WH; Lin JC; Shaw JF; Wang SY
J Ethnopharmacol; 2011 Jun; 136(1):168-77. PubMed ID: 21540101
[TBL] [Abstract][Full Text] [Related]
14. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
[TBL] [Abstract][Full Text] [Related]
15. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
Hosseinpour-Arjmand S; Amirkhizi F; Ebrahimi-Mameghani M
J Clin Pharm Ther; 2019 Apr; 44(2):258-267. PubMed ID: 30585337
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
Zöhrer E; Alisi A; Jahnel J; Mosca A; Della Corte C; Crudele A; Fauler G; Nobili V
Appl Physiol Nutr Metab; 2017 Sep; 42(9):948-954. PubMed ID: 28511023
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
20. The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
Abdallah MS; Eldeen AH; Tantawy SS; Mostafa TM
Eur J Pharmacol; 2021 Sep; 906():174295. PubMed ID: 34214585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
